This week, read about the CDC's analysis on the continuing burden of COVID-19 on a certain population, watch an Emory nurse provide an overview of donning and doffing personal protective equipment when caring for patients with high-consequence infectious disease, a review of diagnostics and treatments for invasive candidiasis, and more.
Kirk Milhoan, MD, PhD, said vaccine choice is the most important element to the public even with the possibility of people contracting this disease or others when given the right to opt out of vaccination.
In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F Kennedy, they announced the termination of the country’s membership in the global health organization.
Although the declared COVID-19 pandemic public health emergency has passed, the CDC reports continued high numbers of illnesses, medical visits, hospitalizations and deaths.
Emory’s Jill Morgan, RN, BSN, discusses what they do after removal of personal protective equipment (PPE) and if a provider has experienced a potential exposure to a high-consequence infectious disease.
Disease management now centers on more precise, context-driven diagnostics, restrained empiric antifungal use, echinocandin-focused therapy, and risk-based ophthalmologic evaluation aligned across global and US guidelines.
Emory’s Jill Morgan, RN, BSN, provides an overview of putting on and taking off personal protective equipment (PPE) when caring for these patients.
Zepto Life Technology has introduced its FungiFlex Mold Panel, a plasma-based molecular test offered through a CLIA-certified reference laboratory that delivers rapid, noninvasive detection of 14 clinically important mold species linked to invasive fungal infections.
Emory’s Katherine Normile, ASCP-MLS, discusses their protocols for safely donning and doffing their equipment when caring for patients with high-consequence infectious disease (HCID) as well as the process for receiving specimens in these care scenarios.
Valneva has voluntarily withdrawn its US regulatory applications for its chikungunya vaccine, IXCHIQ, after the FDA suspended the license and placed the program on clinical hold pending investigation of a newly reported serious adverse event.
In our latest podcast, Jenelle Vargas Musick, DCLS, MPH, MLS(ASCP)CM, provides insights on what these professionals had to deal with during the pandemic as well as how the DCLS credential is preparing laboratory professionals to think strategically about the lab as well as earning a seat at the table for the diagnostic management team.
The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.
Nicholas Van Hise, PharmD, discusses a real world study, ROAR, showing that fecal microbiota, live-jslm (RBL), maintains strong efficacy and safety in preventing recurrent Clostridioides difficile infection (rCDI) in routine US clinical practice.
This week, read articles from our recent issue on topics including invasive fungal disease in transplantation, lenacapavir's role in PrEP, antimicrobial treatment around non–carbapenemase-producing carbapenem-resistant enterobacterales, and more.
Here is a case study of a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal quadruple-valve infective endocarditis involving all 4 heart valves, highlighting the high mortality risk and importance of early recognition, surgical consultation, and substance use treatment.
Evidence supporting the second of two licensed pentavalent meningococcal vaccines as an alternative to separate quadrivalent (ACWY) and serogroup B (MenB) vaccines is described and qualified in a recent MMWR.
We are launching our new monthly column looking at federal regulatory topics including recent decisions. In this column, we look at the FDA approvals of 2 antibiotics last month.
How stewardship teams communicate determines whether interventions feel like policing or collaboration. Using structured, data-driven frameworks— advocacy-inquiry-listen-teach and DART—creates psychological safety to explore understanding and supports shared decision-making.
Infectious disease pediatrician Sharon Nachman, MD, offers insights on the incidence trends among teens, and what severe disease complications look like for young children.
Non–carbapenemase-producing carbapenem-resistant Enterobacterales (CRE) isolates are the most common mechanism of CRE in the United States, but the optimal antimicrobial treatment remains to be elucidated.
Here are some therapeutics and a vaccine that will be reporting data, starting a trial, or filing their data to regulatory agencies in order to seek approval this year.
Invasive fungal diseases remain a major cause of morbidity and mortality in patients undergoing transplant, with shifting epidemiology, emerging resistance, and geographic variation underscoring the urgent need for improved surveillance, prevention strategies, and antifungal stewardship.
The twice-yearly injectable, which significantly reduces HIV incidence compared with oral regimens, has high adherence and manageable adverse effects.
The COVID-19 pandemic intensified long-standing problems in scientific production and communication—driven by perverse academic incentives, peer review strain, media hype, and growing misuse of AI—highlighting the urgent need for stronger critical appraisal skills across research and medicine.
This week, listen in on commentary around the changes to the childhood vaccine schedule, read SIDP's column on the next-generation antifungals as well as combination therapeutics for Candida auris, and the Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing breakpoint recommendations.
Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.
The subcommittee approved the removal of doxycycline and tetracycline breakpoints, revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.
Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, discusses her approach to training for these care scenarios.
Findings from a recent study challenge the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.
A recent study examined how rurality and the availability of postdischarge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.
